ArticleERJ open research2022
Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab.
Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Systemic-airway eosinophil discordance and sputum mediator profiling in severe asthma treated with biologics: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Biological treatments for asthma and chronic obstructive pulmonary disease.BMJ medicine · 2026Review
- The Establishment of a Registry of Respiratory Patients Attending Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Feasibility Study.Ethiopian journal of health sciences · 2025Article
- Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.The Journal of allergy and clinical immunology · 2025Article
- Type-2 Inflammation in Health and Disease: Prevalence, Risk Factors and Multimorbidity.Journal of clinical medicine · 2024Article
- Review
- Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.Thorax · 2023Article
- Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy.Pharmaceutics · 2023Review
- Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma.Frontiers in medicine · 2023Review
- Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023Article
- Galectin-10 as a Potential Biomarker for Eosinophilic Diseases.Biomolecules · 2022Review
- Recent insights in the role of biomarkers in severe asthma management.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.